default author photo

Klaus Seppi

Medical University of Innsbruck

Innrain 52

Christoph-Probst-Platz

Innsbruck, 6020

Austria

  • Medical University of Innsbruck

SCHOLARLY PAPERS

1

DOWNLOADS

144

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

PADOVA: A Phase IIb, Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Individuals with Early-Stage Parkinson Disease on Stable Symptomatic Monotherapy

Number of pages: 39 Posted: 06 Feb 2026
Tania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, Dylan Trundell, Thomas Kustermann, Tanya Simuni, Ken Marek, Nicola Pavese, Klaus Seppi, Fabrizio Stocchi, Ronald B. Postuma, Nathalie Pross, Annabelle Monnet, Gesine Respondek, Valerie Schlegel, Lauren Boak, Loes Rutten-Jacobs, Geoff Kerchner, Patrik Brundin, Hanno Svoboda, Azad Bonni and PADOVA Investigators and Prasinezumab Study Group
F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd, Northwestern University (Philippines) - Department of Neurology, Institute for Neurodegenerative Disorders, Newcastle University, Medical University of Innsbruck, University San Raffaele Roma, McGill University - Montreal General Hospital, Roche, F Hoffmann-La Roche Ltd, Roche, Roche, Roche, Roche, F Hoffmann-La Roche Ltd, Roche - Roche Pharma Research and Early Development, F Hoffmann-La Roche Ltd, F Hoffmann-La Roche Ltd and affiliation not provided to SSRN
Downloads 144 (592,433)

Abstract:

Loading...

alpha-synuclein, clinical trial, monoamine oxidase, levodopa, monoclonal antibodies, Parkinson's disease